Tenax Therapeutics (TENX) Gains from Investment Securities (2013 - 2026)
Tenax Therapeutics recorded quarterly Gains from Investment Securities of $7.9 million in Q1 2026, up 19.02% quarter-over-quarter from $6.6 million in Q4 2025, and up 151.88% year-over-year from $3.1 million in Q1 2025.
Tenax Therapeutics' Gains from Investment Securities history runs 11 years deep, the most recent figure standing at $7.9 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 151.88% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $7.9 million (up 151.88% YoY), while the FY2025 annual figure was $6.6 million, up 111.63% from the prior year.
- Gains from Investment Securities came in at $7.9 million for Q1 2026 at Tenax Therapeutics, up from $6.6 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $7.9 million in Q1 2026 to a low of -$4896.0 in Q2 2023.
- A 4-year average of $2.6 million and a median of $3771.0 in 2023 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities slumped 95.69% in 2023 and surged 151.88% in 2026, its largest moves.
- Tenax Therapeutics' Gains from Investment Securities stood at $2901.0 in 2022, then plunged by 95.69% to $125.0 in 2023, then surged by 5293045.6% to $6.6 million in 2025, then rose by 19.02% to $7.9 million in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $7.9 million, $6.6 million, and $3.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.87 Mn |
| Mar 31, 2026 | 7.87 Mn |
| Dec 31, 2025 | 6.62 Mn |
| Dec 31, 2025 | 6.62 Mn |
| Sep 30, 2025 | 3.00 |
| Sep 30, 2025 | 3.00 |
| Jun 30, 2025 | 6.06 Mn |
| Jun 30, 2025 | 6.06 Mn |
| Mar 31, 2025 | 3.13 Mn |
| Mar 31, 2025 | 3.13 Mn |
| Dec 31, 2023 | 125.00 |
| Dec 31, 2023 | 125.00 |
| Jun 30, 2023 | -4,896.00 |
| Jun 30, 2023 | -4,896.00 |
| Mar 31, 2023 | 3,771.00 |
| Mar 31, 2023 | 3,771.00 |
| Dec 31, 2022 | 2,901.00 |
| Dec 31, 2022 | 2,901.00 |
| Dec 31, 2019 | 244,206.00 |
| Dec 31, 2019 | 244,206.00 |
| Sep 30, 2019 | 2,500.00 |
| Sep 30, 2019 | 2,500.00 |
| Jun 30, 2019 | 191,729.00 |
| Jun 30, 2019 | 191,729.00 |
| Dec 31, 2018 | 85,900.00 |
| Dec 31, 2018 | 85,900.00 |
| Sep 30, 2018 | 100,000.00 |
| Sep 30, 2018 | 100,000.00 |
| Jun 30, 2018 | 100,000.00 |
| Jun 30, 2018 | 100,000.00 |
| Dec 31, 2017 | 150,000.00 |
| Dec 31, 2017 | 150,000.00 |
| Sep 30, 2017 | 3.79 Mn |
| Sep 30, 2017 | 3.79 Mn |
| Jun 30, 2017 | 4.29 Mn |
| Jun 30, 2017 | 4.29 Mn |
| Sep 30, 2016 | 60,000.00 |
| Sep 30, 2016 | 60,000.00 |
| Jun 30, 2016 | 2.57 Mn |
| Jun 30, 2016 | 2.57 Mn |
| Apr 30, 2015 | 4,785.00 |
| Apr 30, 2015 | 4,785.00 |
| Jan 31, 2015 | 3.69 Mn |
| Jan 31, 2015 | 3.69 Mn |
| Oct 31, 2014 | 50,175.00 |
| Oct 31, 2014 | 50,175.00 |
| Jul 31, 2014 | 50,050.00 |
| Jul 31, 2014 | 50,050.00 |
| Apr 30, 2014 | -2,519.00 |
| Apr 30, 2014 | -2,519.00 |
| Jan 31, 2014 | 39,942.00 |
| Jan 31, 2014 | 39,942.00 |
| Oct 31, 2013 | 50,678.00 |
| Oct 31, 2013 | 50,678.00 |
| Jul 31, 2013 | 51,103.00 |
| Jul 31, 2013 | 51,103.00 |
| Apr 30, 2013 | 11,336.00 |
| Apr 30, 2013 | 11,336.00 |